The epidermal growth factor receptor and its inhibition in cancer therapy

Pharmacology and Therapeutics

Volumn 82, Issue 2-3, 1999, Pages 241-250

  Woodburn, J R ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Angiogenesis; EGFR; Epidermal growth factor receptor; Invasion; Tyrosine kinase inhibitor

Indexed keywords

6 AMINO 4 [(3 BROMOPHENYL)AMINO] 7 (METHYLAMINO)QUINAZOLINE; 8 CHLOROADENOSINE 3',5' PHOSPHATE; CETUXIMAB; CGP 59326A; CISPLATIN; CYTOSTATIC AGENT; EMD 55900; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL MODEL; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CELL ADHESION; CELL CYCLE; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION;

APOPTOSIS; CLINICAL TRIALS; ENZYME INHIBITORS; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 0033063774     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(98)00045-X     Document Type: Conference Paper

References (118)

1. Akiyama S., Gottesman M.M., Hanover J.A., Fitzgerald D.J., Willingham M.C., Pastan I. Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with Pseudomonas exotoxin. J. Cell. Physiol. 120:1984;271-279.
2. Anzai H. Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence. Eur. J. Cancer. 34:1998;558-565.
3. Arkonac B.M., Foster L.C., Sibinga N.E., Patterson C., Lai K., Tsai J.C., Lee M.E., Perrella M.A., Haber E. Vascular endothelial growth factor induces heparin-binding epidermal growth factor-like growth factor in vascular endothelial cells. J. Biol. Chem. 273:1998;4400-4405.
4. Baguley B.C., Marshal E.S., Holdaway K.M., Rewcastle G.W., Denny W.A. Inhibition of growth of primary human tumour cell cultures by a 4-anilinoquinazoline inhibitor of the epidermal growth factor receptor family of tyrosine kinases. Eur. J. Cancer. 34:1998;1086-1090.
5. Bartlett J.M., Langdon S.P., Simpson B.J., Stewart M., Katsaros D., Sismondi P., Love S., Scott W.N., Williams A.R., Lessells A.M., Macleod K.G., Smyth J.F., Miller W.R. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer. 73:1996;301-306.
6. Baselga J., Norton L., Masui H., Pandiella A., Coplan K., Miller W.H. Jr., Mendelsohn J. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J. Natl. Cancer Inst. 85:1993;1327-1333.
7. Beckmann M.W., Niederacher D., Massenkeil G., Tutschek B., Beckmann A., Schenko G., Schnurch H.G., Bender H.G. Expression analyses of epidermal growth factor receptor and HER-2/neu. no advantage of prediction of recurrence or survival in breast cancer patients Oncology. 53:1996;441-447.
8. Bos M., Mendelsohn J., Bowden C., Pfister D., Cooper M.R., Cohen R., Burtness B., D'Andrea G., Waksal H., Norton L., Baselga J. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors. Proc. Am. Soc. Clin. Oncol. 15:1996;A1381.
9. Bridges A.J. The current status of tyrosine kinase inhibitors. do the diarylamine inhibitors of the EGF receptor represent a new beginning? Expert Opin. Ther. Patents. 5:1995;1245-1257.
10. Bucci B., D'Agnano I., Botti C., Mottolese M., Carico E., Zupi G., Vecchione A. EGF-R expression in ductal breast cancer. proliferation and prognostic implications Anticancer Res. 17:1997;769-774.
11. Chambers A.F., Matrisian L.M. Changing views of the role of matrix metalloproteinases in metastasis. J. Natl. Cancer Inst. 89:1997;1260-1270.
12. Chen P., Gupta K., Wells A. Cell movement elicited by epidermal growth factor receptor requires kinase and autophosphorylation but is separable from mitogenesis. J. Cell Biol. 124:1994;547-555.
13. Chow N.H., Liu H.S., Lee E.I., Chang C.J., Chan S.H., Cheng H.L., Tzai T.S., Lin J.S. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 17:1997;1293-1296.
14. Ciardiello F., Tortora G. Interactions between the epidermal growth factor receptor and type I protein kinase A. biological significance and therapeutic implications Clin. Cancer Res. 4:1998;821-828.
15. Ciardiello F., Damiano V., Bianco R., Bianco C., Fontanini G., De Laurentiis M., De Placido S., Mendelsohn J., Bianco A.R., Tortora G. Antitumor activity of combined blockade of epidermal growth factor receptor and protein kinase A. J. Natl. Cancer Inst. 88:1996;1770-1776.
16. Davies D.E., Chamberlin S.G. Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem. Pharmacol. 51:1996;1101-1110.
17. de Jong J.S., van Diest P.J., van der Valk P., Baak J.P. Expression of growth factors, growth-inhibiting factors, and their receptors in invasive breast cancer. II. Correlations with proliferation and angiogenesis. J. Pathol. 184:1998;53-57.
18. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146:1995;1029-1039.
19. Eccles S.A., Modjtahedi H., Box G., Court W., Sandle J., Dean C.J. Significance of the c-erbB family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy. Invasion Metastasis. 14:1994;337-348.
20. El-Obeid A., Bongcam-Rudloff E., Sorby M., Ostman A., Nister M., Westermark B. Cell scattering and migration induced by autocrine transforming growth factor alpha in human glioma cells in vitro. Cancer Res. 57:1997;5598-5604.
21. Ennis B.W., Lippman M.E., Dickson R.B. The EGF receptor system as a target for antitumor therapy. Cancer Invest. 9:1991;553-562.
22. Fan Z., Baselga J., Masui H., Mendelsohn J. Antitumour effect of anti-epidermal growth factor monoclonal antibodies plus cisdiamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 53:1993;4637-4642.
23. Fischer-Colbrie J., Witt A., Heinzl H., Speiser P., Czerwenka K., Sevelda P., Zeillinger R. EGFR and steroid receptors in ovarian carcinoma. comparison with prognostic parameters and outcome of patients Anticancer Res. 17:1997;613-619.
24. FitzGerald D.J., Padmanabhan R., Pastan I., Willingham M.C. Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell. 32:1983;607-617.
25. Fontanini G., De Laurentiis M., Vignati S., Chine S., Lucchi M., Silvestri V., Mussi A., De Placido S., Tortora G., Bianco A.R., Gullick W., Angeletti C.A., Bevilacqua G., Ciardiello F. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer. amphiregulin and microvessel count are independent prognostic indicators of survival Clin. Cancer Res. 4:1998;241-249.
26. Fox S.B., Gatter K.C., Harris A.L. Tumour angiogenesis. J. Pathol. 179:1996;232-237.
27. Fujino S., Enokibori T., Tezuka N., Asada Y., Inoue S., Kato H., Mori A. A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer. Eur. J. Cancer. 32A:1996;2070-2074.
28. Genersch E., Schneider D.W., Sauer G., Khazaie K., Schuppan D., Lichtner R.B. Prevention of EGF-modulated adhesion of tumor cells to matrix proteins by specific EGF receptor inhibition. Int. J. Cancer. 75:1998;205-209.
29. Gibson K.H., Grundy W., Godfrey A.A., Woodburn J.R., Ashton S.A., Curry B.J., Scarlett L., Barker A.J., Brown D.S. Epidermal growth factor receptor tyrosine kinase - structure-activity relationships and antitumour activity of novel quinazolines. Bioorg. Med. Chem. Lett. 7:1997;2723-2728.
30. Gille J., Swerlick R.A., Caughman S.W. Transforming growth factor-alpha-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J. 16:1997;750-759.
31. Giordano A., Rustum Y.M., Wenner C.E. Cell cycle. molecular targets for diagnosis and therapy: tumor suppressor genes and cell cycle progression in cancer J. Cell. Biochem. 70:1998;1-7.
32. Goldstein N.I., Prewett M., Zuklys K., Rockwell P., Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res. 1:1995;1311-1318.
33. Gonzalez G., Crombet T., Catala M., Mirabal V., Hernandez J.C., Gonzalez Y., Marinello P., Guillen G., Lage A. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein. report of a pilot clinical trial Ann. Oncol. 9:1998;431-435.
34. Grandis J.R., Chakraborty A., Zeng Q., Melhem M.F., Tweardy D.J. Downmodulation of TGF-alpha protein expression with antisense oligonucleotides inhibits proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. J. Cell. Biochem. 69:1998;55-62. a.
35. Grandis J.R., Melhem M.F., Gooding W.E., Day R., Holst V.A., Wagener M.M., Drenning S.D., Tweardy D.J. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst. 90:1998;824-832. b.
36. Grotendorst G.R., Soma Y., Takehara K., Charette M. EGF and TGF-alpha are potent chemoattractants for endothelial cells and EGF-like peptides are present at sites of tissue regeneration. J. Cell. Physiol. 139:1989;617-623.
37. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:1996;353-364.
38. Hazan R.B., Norton L. The epidermal growth factor receptor modulates the interaction of E-cadherin with the actin cytoskeleton. J. Biol. Chem. 273:1998;9078-9084.
39. He Y., Zeng Q., Drenning S.D., Melhem M.F., Tweardy D.J., Huang L., Grandis J.R. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J. Natl. Cancer Inst. 90:1998;1080-1087.
40. Hirota N., Ueda M., Ozawa S., Abe O., Shimizu N. Suppression of an epidermal growth factor receptor-hyperproducing tumor by an immunotoxin conjugate of gelonin and a monoclonal anti-epidermal growth factor receptor antibody. Cancer Res. 49:1989;7106-7109.
41. Hoffmann T., Hafner D., Ballo H., Haas I., Bier H. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 17:1997;4419-4425.
42. Ito M., Yoshida K., Kyo E., Ayhan A., Nakayama H., Yasui W., Ito H., Tahara E. Expression of several growth factors and their receptor genes in human colon carcinomas. Virchows Arch. B Cell. Pathol. Incl. Mol. Pathol. 59:1990;173-178.
43. Karnes W.E., Weller S.G., Adjei P.N., Kottke T.J., Glenn K.S., Gores G.J., Kaufmann S.H. Inhibition of epidermal growth factor receptor kinase induces protease-dependent apoptosis in human colon cancer cells. Gastroenterology. 114:1998;930-939.
44. Kelly H., Laight A., Morris C.Q., Woodburn J.R., Richmond G. Phase 1 data of ZD1839 - an oral epidermal growth factor receptor tyrosine kinase inhibitor. Ann. Oncol. 9(Suppl. 2):1998;109.
45. Kerbel R.S., Viloria-Petit A., Okada F., Rak J. Establishing a link between oncogenes and tumor angiogenesis. Mol. Med. 4:1998;286-295.
46. Khokha R., Denhardt D.T. Matrix metalloproteinases and tissue inhibitor of metalloproteinases. a review of their role in tumorigenesis and tissue invasion Invasion Metastasis. 9:1989;391-405.
47. Kiyokawa N., Lee E.K., Karunagaran D., Lin S.Y., Hung M.C. Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor. J. Biol. Chem. 272:1997;18656-18665.
48. Klijn J.G., Berns P.M., Schmitz P.I., Foekens J.A. The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer. a review on 5232 patients Endocr. Rev. 13:1992;3-17.
49. Klohs W.D., Fry D.W., Kraker A.J. Inhibitors of tyrosine kinase. Curr. Opin. Oncol. 9:1997;562-568.
50. Kondapaka S.B., Fridman R., Reddy K.B. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int. J. Cancer. 70:1997;722-726.
51. Koullias G.J., Kouraklis G.P., Raftopoulos I.S., Davaris P.S., Papadopoulos S.A., Golematis B.C. Increased estrogen receptor and epidermal growth factor receptor gene product co-expression in surgically resected gastric adenocarcinomas. J. Surg. Oncol. 63:1996;166-171.
52. Kristensen G.B., Holm R., Abeler V.M., Trope C.G. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma. An immunohistochemical study. Cancer. 78:1996;433-440.
53. Kulik G., Klippel A., Weber M.J. Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol. Cell. Biol. 17:1997;1595-1606.
54. Kuratomi Y., Akiyama S., Ono M., Shiraishi N., Shimada T., Ohkuma S., Kuwano M. Thioridazine enhances lysosomal accumulation of epidermal growth factor and toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin. Exp. Cell Res. 162:1986;436-448.
55. Lavelle F. American Association for Cancer Research 1997. progress and new hope in the fight against cancer Expert Opin. Invest. Drugs. 6:1997;771-775.
56. Lawrence D.S., Niu J. Protein kinase inhibitors. Pharmacol. Ther. 77:1998;81-114.
57. Levitzki A. Signal transduction therapy. Eur. J. Biochem. 226:1994;1-3.
58. Levitzki A. Targeting signal transduction for disease therapy. Med. Oncol. 14:1997;83-89.
59. Levitzki A., Gazit A. Tyrosine kinase inhibition. an approach to drug development Science. 267:1995;1782-1788.
60. Lydon N.B., Mett H., Mueller M., Becker M., Cozens R.M., Stover D., Daniels D., Traxler P., Buchdunger E. A potent protein-tyrosine kinase inhibitor which selectively blocks proliferation of epidermal growth factor receptor-expressing tumor cells in vitro and in vivo. Int. J. Cancer. 76:1998;154-163.
61. MacDougall J.R., Matrisian L.M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 14:1995;351-362.
62. Malecka-Panas E., Kordek R., Biernat W., Tureaud J., Liberski P.P., Majumdar A.P. Differential activation of total and EGF receptor (EGF-R) tyrosine kinase (tyr-k) in the rectal mucosa in patients with adenomatous polyps, ulcerative colitis and colon cancer. Hepatogastroenterology. 44:1997;435-440.
63. Mellon J.K., Cook S., Chambers P., Neal D.E. Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor. Br. J. Cancer. 73:1996;654-658.
64. Mendelsohn J., Fan Z. Epidermal growth factor receptor family and chemosensitization. J. Natl. Cancer Inst. 89:1997;341-343.
65. Messa C. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol. 37:1998;285-289.
66. Modjtahedi H., Affleck K., Stubberfield C., Dean C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int. J. Oncol. 13:1998;335-342.
67. Moyer J.D., Barbacci E.G., Iwata K.K., Arnold L., Boman B., Cunningham A., DiOrio C., Doty J., Morin M.J., Moyer M.P., Neveu M., Pollack V.A., Pustilnik L.R., Reynolds M.M., Sloan D., Theleman A., Miller P. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 57:1997;4838-4848.
68. Nagane M., Coufal F., Lin H., Bogler O., Cavenee W.K., Huang H.J. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res. 56:1996;5079-5086.
69. Narita T., Kawakami-Kimura N., Sato M., Matsuura N., Higashiyama S., Taniguchi N., Kannagi R. Alteration of integrins by heparin-binding EGF-like growth factor in human breast cancer cells. Oncology. 53:1996;374-381.
70. Niikura H., Sasano H., Sato S., Yajima A. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int. J. Gynecol. Pathol. 16:1997;60-68.
71. Normanno N., De Luca A., Salomon D.S., Ciardiello F. Epidermal growth factor-related peptides as targets for experimental therapy of human colon carcinoma. Cancer Detect. Prev. 22:1998;62-67.
72. Nutt J.E., Mellon J.K. Matrix metalloproteinase-1 is induced by epidermal growth factor in human bladder tumour cell lines and is detectable in urine of patients with bladder tumours. Br. J. Cancer. 78:1998;215-220.
73. Parker C., Roseman B.J., Bucana C.D., Tsan R., Radinsky R. Preferential activation of the epidermal growth factor receptor in human colon carcinoma liver metastases in nude mice. J. Histochem. Cytochem. 46:1998;595-602.
74. Peng D., Fan Z., Lu Y., DeBlasio T., Scher H., Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res. 56:1996;3666-3669.
75. Perry J.E., Grossmann M.E., Tindall D.J. Epidermal growth factor induces cyclin D1 in a human prostate cancer cell line. Prostate. 35:1998;117-124.
76. Potgens A.J., Westphal H.R., de Waal R.M., Ruiter D.J. The role of vascular permeability factor and basic fibroblast growth factor in tumor angiogenesis. Biol. Chem. Hoppe Seyler. 376:1995;57-70.
77. Powis G. Signaling pathways as targets for anticancer drugs. Pharmacol. Ther. 62:1994;57-95.
78. Prakash I., Mathur R.P., Kar P., Ranga S., Talib V.H. Comparative evaluation of cell proliferative indices and epidermal growth factor receptor expression in gastric carcinoma. Indian J. Pathol. Microbiol. 40:1997;481-490.
79. Prewett M., Rockwell P., Rockwell R.F., Giorgio N.A., Mendelsohn J., Scher H.I., Goldstein N.I. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J. Immunother. Emphasis Tumor Immunol. 19:1996;419-427.
80. Price J.T., Wilson H.M., Haites N.E. Epidermal growth factor (EGF) increases the in vitro invasion, motility and adhesion interactions of the primary renal carcinoma cell line, A704. Eur. J. Cancer. 32A:1996;1977-1982.
81. Rabbani S.A., Xing R.H. Role of urokinase (uPA) and its receptor (uPAR) in invasion and metastasis of hormone-dependent malignancies. Int. J. Oncol. 12:1998;911-920.
82. Radinsky R., Risin S., Fan D., Dong Z., Bieelenberg D., Bucana C.D., Fidler I. Level and function of epidermal growth factor receptor predicts the metastatic potential of human colon carcinoma cells. Clin. Cancer Res. 1:1995;19-31.
83. Ravery V., Grignon D., Angulo J., Pontes E., Montie J., Crissman J., Chopin D. Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer. Urol. Res. 25:1997;9-17.
84. Rodeck U., Jost M., Kari C., Shih D.T., Lavker R.M., Ewert D.L., Jensen P.J. EGF-R dependent regulation of keratinocyte survival. J. Cell Sci. 110:1997;113-121.
85. Rosen E.M., Goldberg I.D. Protein factors which regulate cell motility. In Vitro Cell Dev. Biol. 25:1989;1079-1087.
86. Saeki T., Salomon D.S., Johnson G.R., Gullick W.J., Mandai K., Yamagami K., Moriwaki S., Tanada M., Takashima S., Tahara E. Association of epidermal growth factor-related peptides and type I receptor tyrosine kinase receptors with prognosis of human colorectal carcinomas. Jpn. J. Clin. Oncol. 25:1995;240-249.
87. Salomon D.S., Brandt R., Ciardiello F., Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol./Haematol. 19:1995;183-232.
88. Schreiber A.B., Winkler M.E., Derynck R. Transforming growth factor-alpha. a more potent angiogenic mediator than epidermal growth factor Science. 232:1986;1250-1253.
89. Shao Z.M., Wu J., Shen Z.Z., Barsky S.H. Genistein inhibits both constitutive and EGF-stimulated invasion in ER-negative human breast carcinoma cell lines. Anticancer Res. 18:1998;1435-1440.
90. Shibata T., Kawano T., Nagayasu H., Okumura K., Arisue M., Hamada J., Takeichi N., Hosokawa M. Enhancing effects of epidermal growth factor on human squamous cell carcinoma motility and matrix degradation but not growth. Tumour Biol. 17:1996;168-175.
91. Shugar D. Protein kinase inhibitors - potential chemotherapeutic agents. Acta Biochim. Pol. 42:1995;405-418.
92. Taetle R., Honeysett J.M., Houston L.L. Effects of anti-epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate on growth of human cells. J. Natl. Cancer Inst. 80:1988;1053-1059.
93. Torregrosa D., Bolufer P., Lluch A., Antonio Lopez J., Barragan E., Ruiz A., Guillem V., Munarriz B., Conde J.G. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status. Clin. Chim. Acta. 262:1997;99-119.
94. Traxler P. Protein tyrosine kinase inhibitors in cancer treatment. Exp. Opin. Ther. Patents. 7:1997;571-588.
95. Turkeri L.N., Erton M.L., Cevik I., Akdas A. Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology. 51:1998;645-649.
96. Turner T., Chen P., Goodly L.J., Wells A. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin. Exp. Metastasis. 14:1996;409-418.
97. Uckun F.M., Narla R.K., Jun X., Zeren T., Venkatachalam T., Waddick K.G., Rostostev A., Myers D.E. Cytotoxic activity of epidermal growth factor-genistein against breast cancer cells. Clin. Cancer Res. 4:1998;901-912. a.
98. Uckun F.M., Narla R.K., Zeren T., Yanishevski Y., Myers D.E., Waurzyniak B., Ek O., Schneider E., Messinger Y., Chelstrom L.M., Gunther R., Evans W. In vivo toxicity, pharmacokinetics, and anticancer activity of genistein linked to recombinant human epidermal growth factor. Clin. Cancer Res. 4:1998;1125-1134. b.
99. Uegaki K., Nio Y., Inoue Y., Minari Y., Sato Y., Song M.M., Dong M., Tamura K. Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res. 17:1997;3841-3847.
100. Uhlman D.L., Adams G., Knapp D., Aeppli D.M., Niehans G. Immunohistochemical staining for markers of future neoplastic progression in the larynx. Cancer Res. 56:1996;2199-2205.
101. Verbeek B.S., Adriaansen-Slot S.S., Vroom T.M., Beckers T., Rijksen G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett. 425:1998;145-150.
102. Viloria Petit A.M., Rak J., Hung M.C., Rockwell P., Goldstein N., Fendly B., Kerbel R.S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. angiogenic implications for signal transduction therapy of solid tumors Am. J. Pathol. 151:1997;1523-1530.
103. Vollmar A.M., Banker D.E., Mendelsohn J., Herschman H.R. Toxicity of ligand and antibody-directed ricin A-chain conjugates recognizing the epidermal growth factor receptor. J. Cell. Physiol. 131:1987;418-425.
104. Volm M., Rittgen W., Drings P. Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas. Br. J. Cancer. 77:1998;663-669.
105. Wakeling A.E., Barker A.J., Davies D.H., Brown D.S., Green L.R., Cartlidge S.A., Woodburn J.R. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat. 38:1996;67-73.
106. Wang S., Lee R.J., Cauchon G., Gorenstein D.G., Low P.S. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycol. Proc. Natl. Acad. Sci. USA. 92:1995;3318-3322.
107. Ward W.H., Cook P.N., Slater A.M., Davies D.H., Holdgate G.A., Green L.R. Epidermal growth factor receptor tyrosine kinase. Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor. Biochem. Pharmacol. 48:1994;659-666.
108. Watabe T., Yoshida K., Shindoh M., Kaya M., Fujikawa K., Sato H., Seiki M., Ishii S., Fujinaga K. The Ets-1 and Ets-2 transcription factors activate the promoters for invasion-associated urokinase and collagenase genes in response to epidermal growth factor. Int. J. Cancer. 77:1998;128-137.
109. Wersall P., Ohlsson I., Biberfeld P., Collins V.P., von Krusenstjerna S., Larsson S., Mellstedt H., Boethius J. Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol. Immunother. 44:1997;157-164.
110. Woodburn J.R., Barker A.J. 4-Anilinoquinazolines - a potential new therapy for major human solid tumors overexpressing the EGF receptor. Br. J. Cancer. 74:1996;18.
111. Woodburn J.R., Barker A.J., Wakeling A.E., Valcaccia B.E., Cartlidge S.A., Davies D.H. 6-Amino-4(3-methylphenylamino)-quinazoline. an EGF receptor tyrosine kinase inhibitor with activity in a range of human tumour xenografts Proc. Am. Assoc. Cancer Res. 37:1996;390-391.
112. Woodburn J.R., Barker A.J., Gibson K.H., Wakeling A.E., Curry B.J., Scarlett L., Henthorn L.R. ZD1839, an epidermal growth factor tyrosine kinase inhibitor selected for clinical development. Proc. Am. Assoc. Cancer Res. 38:1997;633-634.
113. Wu X., Fan Z., Masui H., Rosen N., Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. 95:1995;1897-1905.
114. Wu X., Rubin M., Fan Z., DeBlasio T., Soos T., Koff A., Mendelsohn J. Involvement of p27KIP1 in G1 arrest mediated by an anti-epidermal growth factor receptor monoclonal antibody. Oncogene. 12:1996;1397-1403.
115. Xie H., Turner T., Wang M.H., Singh R.K., Siegal G.P., Wells A. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin. Exp. Metastasis. 13:1995;407-419.
116. Yasui W., Hata J., Yokozaki H., Nakatani H., Ochiai A., Ito H., Tahara E. Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int. J. Cancer. 41:1988;211-217.
117. Yonemura Y., Takamura H., Ninomiya I., Fushida S., Tsugawa K., Kaji M., Nakai Y., Ohoyama S., Yamaguchi A., Miyazaki I. Interrelationship between transforming growth factor-alpha and epidermal growth factor receptor in advanced gastric cancer. Oncology. 49:1992;157-161.
118. Zhu A., Shaeffer J., Leslie S., Kolm P., El-Mahdi A.M. Epidermal growth factor receptor. an independent predictor of survival in astrocytic tumors given definitive irradiation Int. J. Radiat. Oncol. Biol. Phys. 34:1996;809-815.